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Abstract
Objective: The classical Hodgkin lymphoma (cHL) tumor microenvironment shows an 
ongoing inflammatory response consisting of varying degrees of infiltrating eosino-
phils, mast cells, macrophages, regulatory T lymphocytes (Tregs), and activated lym-
phocytes surrounding the malignant cells. Herein, different immune signatures are 
characterized and correlated with treatment outcome.
Methods: Tumor- infiltrating leukocytes were phenotyped in biopsies from 459 pa-
tients with cHL. Time to progression (TTP) (primary progression, relapse, or death from 
cHL) and overall survival were analyzed using Cox proportional hazards regression.
Results: The leukocyte infiltration in the microenvironment was highly diverse be-
tween patients and was categorized in 4 immune signatures (active, anergic, innate, or 
mixed). A high proportion of Tregs (anergic) resulted in shorter TTP (median 12.9- year 
follow- up) in age- adjusted analyses (hazard ratio = 1.82; 95% confidence interval 
1.05- 3- 15). Epstein- Barr virus (EBV)- positive cases had higher proportions of mac-
rophages and activated lymphocytes than EBV negative, but neither of those leuko-
cytes predicted prognosis.
Conclusions: Abundant Tregs (anergic signature) indicate a shorter TTP, particularly in 
younger patients. This is probably due to a reduced ability of the immune system to 
attack the tumor cells. Our data warrant further investigation if these suggested im-
mune signatures could predict outcome of immunotherapy such as immune check-
point inhibitors.
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1  | INTRODUCTION
Despite the excellent overall survival (OS) in classical Hodgkin lym-
phoma (cHL), some patients suffer progression or relapse.1 For these 
patients, antibody- drug conjugates and immune checkpoint inhibitors 
have been introduced as an alternative and/or addition to high- dose 
chemotherapy with stem cell support. It remains to be established if 
patients with high risk of treatment failure may benefit from these 
agents as front- line treatment.1 The malignant Hodgkin and Reed- 
Sternberg cells (HRS) in cHL are of B lymphocyte origin and constitute 
only a few percent of the tumor mass. The rest of the lesion consists 
of fibroblasts and leukocytes, such as granulocytes, mast cells, mac-
rophages, and various T and B lymphocytes. The interplay between 
the leukocytes and the HRS cells is associated with tumor progression 
and with the ability of the tumor cells to evade the patients’ immune 
response.2 Galon et al3 studied total T lymphocytes (CD3), cytotoxic T 
lymphocytes (CD8), and memory T lymphocytes (CD45RO) on tumor 
tissue sections with immunohistochemical markers in colorectal car-
cinoma. High numbers of each marker in the center of the tumor and 
in the invasive margin were independently associated with superior 
outcome and were superior predictors of outcome compared to the 
TNM- classification.3 However, hematological malignancies such as 
cHL differ from solid carcinomas in several aspects. First, the cHL mi-
croenvironment does not contain central parts and invasive margins. 
Second, the malignant HRS cells are scarce compared to the surround-
ing infiltrate of leukocytes.2
A certain immune signature might be predictive of response to 
conventional therapy but may also provide guidance to possible re-
sponders of immune checkpoint inhibitors. The prognostic signif-
icance of different tumor- infiltrating leukocytes in cHL has been 
studied extensively but is still unclear due to ambiguous results,2 and 
no previous study has tried to determine a distinct immune signature 
associated with inferior outcome.3 In a recent publication from our 
research group on a pediatric population with cHL,4 high numbers of 
mast cells and macrophages correlated with advanced stage and labo-
ratory parameters associated with dismal outcome.
In this study, our aim was to investigate if a certain immune signa-
ture correlates with outcome by studying a limited number of leuko-
cytes, analogous to the approach by Galon et al3 but adjusted to the 
cHL microenvironment. Based on previous studies, a high number of 
activated lymphocytes (including cytotoxic T lymphocytes (CTL) and 
natural killer (NK) cells)5 was defined as an active immune signature, a 
high number of regulatory T lymphocytes (Tregs) as an anergic immune 
signature,6 and a high number of eosinophils,7 mast cells,8 and macro-
phages,9,10 respectively, as an innate immune signature. As activated 
lymphocytes are able to kill tumor cells, Tregs maintain an immune 
suppressive state in tumors,11 and eosinophils, mast cells, and macro-
phages support tumor cell growth by maintaining chronic inflamma-
tion, our a priori hypothesis was that prognosis should be poorer for 
patients with an anergic or innate immune signature compared with 
patients with an active immune signature. We studied these leuko-
cytes in tumor sections from 459 cHL patients and correlated the 
findings with clinical characteristics, including OS and time to progres-
sion (TTP).
2  | MATERIALS AND METHODS
2.1 | Patients
In the Scandinavian Lymphoma Etiology (SCALE) study, a population- 
based case- control study of Swedish and Danish patients aged 18- 
74 years diagnosed between January 1999 and August 2002,12 585 
patients with cHL (nodular sclerosis, mixed cellularity (MC), lympho-
cyte rich, lymphocyte depleted, and not otherwise specified) were 
included13 (Figure 1). All patients were also interviewed for poten-
tial risk factors for cHL, and clinical data were gathered. The current 
study included 459 SCALE patients from whom diagnostic tumor 
biopsies were available for assessment of infiltrating leukocytes and 
Epstein- Barr virus (EBV) status. Tumor material was gathered from 
Danish and Swedish pathology departments, and re- evaluated to 
confirm the initial diagnosis within the lymphoma registry (LYFO) 
in Denmark and by 6 designated hematopathologists in Sweden. 
Clinical information was collected from medical records in Sweden 
and/or from LYFO in Denmark12,14 and was available for 409 pa-
tients. Patients with a history of a previous hematologic malignancy, 
organ transplantation, or human immunodeficiency virus infection 
were excluded.
Patients with stage I- IIA at diagnosis were treated with 2- 4 chemo-
therapy courses and involved- field radiotherapy. Patients with stage 
IIB- IV were treated with 6- 8 courses of chemotherapy and additional 
radiotherapy in case of bulky tumor, residual tumor tissue, or slow 
tumor regression.15 Chemotherapy used was mainly ABVD (adriamy-
cin, bleomycin, vinblastine, and dacarbazine) or BEACOPP (bleomycin, 
etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, 
and prednisone).1 In Sweden, BEACOPP was used in patients with ad-
vanced stage and an International Prognostic Score >2. Most patients 
above 65 years of age were treated with CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone).
2.2 | Immunohistochemical staining
Slides were prepared using 3- 4 μm thick sections cut from paraffin- 
embedded tumor material from diagnostic biopsies. For a part of the 
Swedish material (n = 128), tissue microarrays (TMA) with 2 cores per 
patient (1 mm in diameter) were prepared from whole lymph node 
surgical diagnostic biopsies. The sections were deparaffinized, antigen 
was retrieved, and each antibody was added for immunohistochemi-
cal stainings. The monoclonal mouse antibody (MoAB) G3 (Chemicon 
International, Temecula, CA, USA, LV1387895), diluted 1:50, stained 
tryptase to identify mast cells. MoAB PG- M1 (Dako, Copenhagen, 
Denmark, M0896), diluted 1:200, stained CD68 to identify mac-
rophages. MoAB mbAbcam–22509 (Abcam, Cambridge, MA, USA), 
diluted 1:50, stained FoxP3 to identify Tregs. MoAB NCL- L- GRAN- B 
(Novocastra, Newcastle, UK), diluted 1:50, stained Granzyme B to 
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identify CTL and NK cells (active lymphocytes). The sections were 
then counterstained with Mayer’s hematoxylin.
2.3 | Evaluation of tumor- infiltrating leukocytes
Eosinophils were evaluated on slides stained with hematoxylin- eosin. 
Eosinophils and mast cells, being homogenous and easily contrasted, 
were evaluated in 10 randomly selected high- power fields (HPF) at 
400 ×  (0.0625 mm2) for eosinophils and 200x (0.25 mm2) magnifica-
tion for mast cells. The number of positive cells within the net area was 
counted in accordance with prior investigations.4,16,17 Macrophages 
were estimated in 6 randomly selected HPFs at 400 ×  magnification 
as the percentage of macrophages in relation to the overall inflamma-
tory cellularity, this since macrophages are heterogeneously shaped. 
Tregs and activated lymphocytes were counted in 3 to 5 randomly se-
lected HPF at 400x magnification. The total number of inflammatory 
cells within a field was counted, with the percentage of Tregs and 
activated lymphocytes then calculated. All inflammatory cells were 
evaluated using a microscope equipped with a lattice square net in 
fields with HRS cells, while fibrotic and necrotic areas were avoided.
2.4 | Categorization of leukocytes
The number and proportion of tumor- infiltrating leukocytes were 
considered as either continuous or categorical variables. Hence, the 
number of eosinophils was categorized as 0- 199 (low) compared 
with 200 or more (200 +; high); the categorical exposure variable 
of 200 +  eosinophils correlated with poor prognosis in a previous 
study.16 The cut- off for a high number of mast cells, a high propor-
tion of macrophages, Tregs, and activated lymphocytes was set to the 
75th percentile (quartile four). This meant that the number of mast 
cells was categorized into 0- 49 (low), and 50 or more (50 + ; high).17 
Each HPF for macrophages was designated a number based on the 
percentage of positive cells: 0%- 5% = 0, 6%- 25% = 1, 26%- 50% = 2, 
and >50% = 3, of positive cells. In ambiguous cases, the total number 
of inflammatory cells within the HPF was counted, with the percent-
age of macrophages then calculated. The amounts were summarized 
(range: 0- 16), and the upper quartile was 8 (high).18,19 The percent-
age of Tregs was categorized into ≥15% (high) vs <15% (low),20 and 
the percentage of activated lymphocytes was categorized into ≥8% 
(high) vs <8% (low).20 Examples of a high vs a low grading are shown in 
Figure 2. The distribution of patients according to the cut- off for each 
leukocyte is illustrated in Fig. S1.
2.5 | Categorization of immune signatures
An active immune signature was defined as a high proportion of acti-
vated lymphocytes (quartile 4, ≥8%) in combination with a low propor-
tion of Tregs (below quartile 4, <15%), an anergic immune signature 
as a high proportion of Tregs (quartile 4, ≥15%), and an innate im-
mune signature as a high number of eosinophils (200 + ), mast cells 
(quartile 4, 50 + ), and macrophages (quartile 4). Patients who fulfilled 
the criteria for both an innate immune signature and either an aner-
gic or active immune signature were characterized as anergic or ac-
tive, respectively. Tumors not possible to categorize into any of these 
groups were considered to have a mixed immune signature. Fifty- four 
patients lacked information on 1 key parameter and could therefore 
not be categorized.
2.6 | Statistical methods
Associations between the leukocytes in the tumor microenviron-
ment in relation to each other and to age, histology, sex, EBV- status, 
bulky tumor (tumor diameter ≥10 cm), limited vs advanced stage, B 
symptoms, extranodal involvement, bone marrow involvement, and 
blood parameters (erythrocyte sedimentation rate (ESR), hemoglobin 
(Hb), white blood cell count (WBC), lymphocytes, and albumin) were 
studied in the entire cohort (Figure 1). If not otherwise specified, age 
was treated as a linear covariate. Correlations between potential 
F IGURE  1 Flowchart of patients included in the study. Hodgkin 
lymphoma patients diagnosed 1999- 2002 in Sweden and Denmark 
in the Scandinavian Lymphoma Etiological Study (SCALE). Number 
of evaluated cases for tumor- infiltrating inflammatory cells, including 
eosinophils, mast cells, macrophages, regulatory T lymphocytes, 
and activated lymphocytes for the entire cohort and for cases with 
available clinical follow- up information. *Not all 459 cases were 
available for evaluation due to lack of remaining tissue
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F IGURE  2  Immunohistochemistry demonstrating high vs low presence of immune cell infiltrates. Infiltrating eosinophils were detected with 
hematoxylin- eosin stain, while other leukocytes were detected by immunohistochemistry: mast cells (tryptase+ cells) macrophages (CD68 +  
cells), Tregs (FoxP3 +  cells), and activated lymphocytes (granzyme B+ cells) as indicated in the figure. Magnification ×400
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prognostic factors were analyzed using the Spearman Rank Order 
Correlation test. Survival was analyzed using Kaplan- Meier curves 
and Cox proportional hazards regression with respect to dichotomous 
clinical predictors. All survival analyses were performed in the clinical 
cohort (Figure 1), and presented for high vs low number/proportion 
of each cell type. Detailed statistical methods on the specific immune 
signatures are indicated in the Supplementary Appendix S1. TTP was 
defined as the time from initial diagnosis to progression of disease, 
including primary progressive disease, relapse, or death from cHL. 
Death from cHL was defined as death with active lymphoma disease 
(after primary progressive disease and/or relapses occurred). OS was 
defined as survival from initial diagnosis to death from any cause. 
To be a participant in the SCALE study, the patient had to answer a 
questionnaire at an interview. To counter the potential survivor bias 
inherent in this left truncation, start of follow- up was delayed until 
the latest of date of diagnosis and date of interview. That is, follow- up 
started at entry into the SCALE study, with time of diagnosis as the 
origin of the underlying time scale for Cox regression. Analyses were 
supplemented by stratification by age above and below 60 years, and 
by stage. Based on earlier experience, we find it likely that putative 
effects may be present only in some strata, while being completely 
absent in other strata and we have therefore taken a stratified ap-
proach recognizing the heterogeneity of cHL, despite relatively low 
statistical power and multiple testing. The statistical analyses were 
performed using SAS version 9.4. Statistical tests were two- sided, and 
P- values < .05 were considered statistically significant. Confidence in-
tervals (CI) for hazard ratios (HR) were based on Wald tests.
2.7 | Ethics
The study was approved by the Danish Data Protection Agency and 
by ethics committees according to the Declaration of Helsinki in both 
countries. Informed consent was obtained from all participants.
3  | RESULTS
3.1 | Macrophages correlate with several well- 
known indicators of inferior prognosis
In the entire cohort of cHL cases, 459 tissue blocks were analyzed 
for eosinophils (n = 444), mast cells (n = 428), macrophages (n = 410), 
Tregs (n = 419), and activated lymphocytes (n = 378) (Figure 1). Tregs 
and activated lymphocytes in the microenvironment were present in 
most cases. Macrophages were present in all cases, and due to their 
size covered a larger part of the total tissue compared to Tregs and 
activated lymphocytes (Figure 2). Correlations between the different 
leukocytes were generally low, indicating that individual tumors dif-
fered phenotypically according to the predominant cell type in the 
microenvironment. Eosinophils were few or not present in the major-
ity of the cases, while some cases showed an extreme eosinophilia. 
Mast cells were usually rare, although present in some cases in ex-
treme numbers. A high number of mast cells correlated weakly with 
a high number of eosinophils and a high proportion of macrophages 
correlated with a high proportion of activated lymphocytes and eo-
sinophils (Table S1). Among clinicopathological parameters, a high 
level of macrophages correlated with EBV- positivity and MC, and with 
well- known negative prognostic factors such as advanced stage, high 
ESR, low Hb, low WBC, bulky tumor, and bone marrow involvement 
(Table S2). Despite this, macrophages were not associated with TTP 
or OS (Table 2 and Table S3). The number of mast cells correlated 
with an elevated ESR (Table S2). A high proportion of Tregs correlated 
with younger age and high WBC while a high proportion of activated 
lymphocytes correlated with EBV- positivity, MC, older age, male sex, 
and low WBC (Table S2).
3.2 | An active or an anergic immune signature is 
equally common
The cases were subdivided into different immune signatures in which 
a high level of activated lymphocytes and a low number of Tregs were 
considered an active signature, a high number of Tregs was consid-
ered an anergic signature, high levels of eosinophils, mast cells, and 
macrophages were considered an innate signature, and cases with 
various immune infiltrates not fitting into the previous signatures 
were defined a mixed signature. Of all evaluable patients, 103 (22%) 
were classified as having an active signature, 112 (24%) an anergic 
signature, and 34 (8%) an innate signature. A mixed immune signature 
was determined in 156 patients (33%). The cell infiltrate changed with 
age at diagnosis, with Tregs more abundant in younger ages. In the 
cohort, 52% of the patients presented with advanced stage, and 29% 
with bulky tumor (Table 1).
3.3 | A high proportion of Tregs (anergic immune 
signature) is associated with inferior outcome
Median follow- up time was 12.9 years. Sixty- two (15%) of 409 pa-
tients experienced an event (progression, relapse, or cHL death). 
Fifty- five of these TTP events occurred within the first 5 years after 
diagnosis, resulting in a 5- year relative TTP survival of 0.83 (95% CI 
0.78- 0.87). A shorter TTP was seen for cases with an anergic immune 
signature (age- adjusted HR = 2.25, [95% CI 1.15- 4.41]), compared 
with cases with a mixed immune signature (Figure 3). Patients with a 
high proportion of Tregs had a shorter TTP also in age- adjusted analy-
sis (Figure 3), represented by a HR of 1.82 (95% CI 1.05- 3.15).
Several well- known clinical prognostic factors were associated 
with a shorter TTP including older age, bulky tumor, and low- serum 
albumin (<40 g/l), reflecting elderly and sick patients at time of diag-
nosis (Table 2). When adjusted for age, stage, albumin (<40 g/l), and 
bulky tumor, the association between high proportion of Tregs and 
TTP was no longer formally significant (HR = 1.44 [95% CI 0.77- 2.85]). 
Point estimates were similar irrespectively of type of chemotherapy 
and still elevated when Tregs were analyzed in groups restricted to 
Swedish patients treated with ABVD (HR = 1.85 [95% CI 0.82- 4.19]), 
or BEACOPP (HR = 1.73 [95% CI 0.47- 6.27]), although statistically in-
significant due to small strata. None of the other immune signature 
groups and none of the other individual cell types (eosinophils, mast 
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cells, macrophages, and activated lymphocytes) were significantly as-
sociated with TTP or OS. However, a high number of eosinophils was 
associated with a superior OS in patients <60 years of age (Table S3), 
and a high proportion of activated lymphocytes was associated with a 
shorter OS in limited stages (Table S3).
4  | DISCUSSION
CHL shows a complex interplay between the immune cell- derived 
HRS cell and its microenvironment. It often presents with a highly 
variable inflammatory infiltrate with an absence of a central part and 
invasive margin which is commonly seen in other tumors as described 
in Galons et als “immunoscore” for colorectal carcinoma.3 Hence, for 
tumors like cHL, there is a need for another type of immune classifica-
tion for correlations to prognosis and possible prediction of patients 
that may benefit from immunotherapeutics such as immune check-
point blockade antibodies.
We attempted herein to define suitable immune signatures for cHL 
in a large cohort of cHL patients treated according to national guidelines 
during a short and well defined time period. We divided the material into 
3 separate immune signature profiles: active (high activated lympho-
cytes and low Tregs), anergic (high Tregs), and innate (high eosinophils, 
high mast cells, and high macrophages). Most patients presented with 
active, anergic, or a mixed immune signature while an innate signature 
was less common. Only an anergic immune signature was associated 
with outcome, namely an inferior TTP. This division, however, added 
no further prognostic information than the Tregs analyzed individually 
(Figure 3). Patients with a high proportion of Tregs had an indication of 
shorter TTP. When adjusted for age, a high proportion of Tregs was still 
associated with a shorter TTP, but not when further adjusted for stage, 
low albumin and bulky tumor, perhaps due to lower statistical power. 
Hence, high amount of Tregs is not an independent marker of inferior 
TABLE  1 Clinical and tumor biological characteristics of patients 
with classical Hodgkin Lymphoma
Entire cohort 
(n, %)
All patients 459 (100)
Epstein- Barr virus positive
Yes 122 (27)
No 319 (69)
Missing 18 (4)
Age
≥45 y 149 (32)
<45 y 310 (68)
Histologic subtype
Nodular sclerosis 346 (75)
Mixed cellularity 85 (19)
Lymphocyte rich + lymphocyte depleted + 
unclassifiable cHL
28 (6)
Stage
IA- IIA 203 (44)
IIB- IVB 237 (52)
Missing 19 (4)
Sex
Male 242 (53)
Female 217 (47)
Erythrocyte sedimentation rate, >50 mm/h
Yes 113 (25)
No 163 (35)
Missing 183 (40)
Hemoglobin, <10.5 g/dL
Yes 61 (13)
No 370 (81)
Missing 28 (6)
White blood cell count, >15x109/L
Yes 38 (8)
No 394 (86)
Missing 27 (6)
Bulky tumor, diameter ≥10 cm
Yes 132 (29)
No 279 (61)
Missing 48 (10)
Bone marrow involvement
Yes 16 (3)
No 370 (81)
Missing 73 (16)
Albumin, <40 g/L
Yes 206 (45)
No 158 (34)
Missing 95 (21)
Entire cohort 
(n, %)
Treatment received (Denmark and Sweden)a
Radiotherapy only 5 (1)
Chemotherapy - RT 128 (31)
Chemotherapy + RT 243 (59)
Missing 33 (8)
Chemotherapy type (Sweden)b
MOPP/ABV 19 (7)
ABVD 171 (65)
BEACOPP 53 (20)
CHOP/LVPP/OEPA 17 (6)
Radiotherapy only 2 (1)
Missing 1 (0)
aClinical cohort (n = 409).
bSwedish clinical cohort (n = 263).
TABLE  1  (Continued)
(Continues)
94  |     HOLLANDER Et AL.
TTP in our cohort. Nevertheless, as HRS cells attract Tregs,2 the number 
of Tregs might increase with tumor load and adjusting statistical calcula-
tion for clinical parameters may be unjust.
4.1 | Possible mechanisms
Tregs are able to suppress various inflammatory cells, not only the an-
titumor functions of CTL, but also NK cells, B lymphocytes, dendritic 
cells, and macrophages.6 Thus, from a biological perspective, a high 
proportion of Tregs could theoretically lead to a reduced ability of the 
immune system to attack the tumor cells and a higher risk of progres-
sion, relapse and death from cHL, in line with our results and our a 
priori hypothesis. Patients with an anergic immune signature may have 
more aggressive tumor biology, causing the anergic state in the tumors, 
and/or a reduced ability to react with a proper immune response.11 
Immune checkpoint inhibitors, such as programed death receptor 1 
(PD- 1) inhibitors, were recently introduced as novel therapy in re-
lapsed and refractory cHL, supposedly acting through re- activation of 
anergic CTL.21,22 PD- 1 is also expressed by Tregs and promotes their 
function and proliferation.23 It is thus possible that the effect of PD- 1 
inhibition is largely mediated through blockade of Tregs.24 Tregs in 
the microenvironment in cHL might thus be a predictor of response to 
PD- 1 blockade, and patients with a high expression of Tregs might be 
a subgroup of patients with a particular high risk of early progression 
and relapse in need of novel treatments already as first line.
4.2 | Comparison with previous studies 
regarding Tregs
In line with our investigation, only 1 previous study reports that a high 
number of Tregs was associated with an inferior outcome among 87 
patients, but only in crude analysis.25 In several other previous studies 
including between 63 and 257 patients, high numbers/proportions of 
Tregs have been associated with a favorable prognosis20,26-31 (sum-
marized in Table S4), which makes our contrasting results of particular 
interest to report. In most prior studies, cases were gathered over sev-
eral decades, and different treatment regimens were used.27,31 Most 
of the studies included patients <18 years of age, which also might in-
fluence treatment given. In elderly patients, other factors than tumor 
biology may affect the prognosis (such as comorbidities), making the 
F IGURE  3 A, Box- plots of distributions of each leukocyte in the cohort. B, Kaplan- Meier estimate of time to progression (TTP) considering 
immune signatures. A shorter TTP was seen for cases with an anergic immune signature (Blue line), (Log- rank test P = .02, age- adjusted HR for 
TTP = 2.25, [95% CI 1.15- 4.41]) compared with cases with a mixed immune signature (Green line). No statistically significant differences for 
TTP were seen between cases with an active (Red line) or innate (Black line) compared with cases with a mixed immune signature (Green line). 
C, Kaplan- Meier estimate of TTP considering regulatory T lymphocytes. A shorter TTP was seen for cases with a high infiltration of regulatory T 
lymphocytes (upper quartile) (Blue line) compared with cases with a low infiltration of regulatory T lymphocytes (Red line) (Log- rank test, P = .03)
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younger age group of particular interest. In addition, various manu-
facturers for the anti- FoxP3 antibody were used, and various cut- offs 
were applied. Also, different outcomes were used, and the definition 
of the same outcome differed between studies (Table S4). A recent 
study that used flow cytometry in cHL patients treated with ABVD, 
found that high numbers of CD8+ and CD4+ lymphocytes were as-
sociated with better and poorer outcomes, respectively.32 Although it 
is unclear how much of the CD4+ population was composed of Tregs, 
these findings are partly in line with ours. Based on our large cohort 
and the biological rationale of our findings, we believe it is too early to 
be definitive in considering a high proportion of Tregs as favorable for 
prognosis, despite the findings of earlier studies.
4.3 | Comparison with previous studies regarding 
eosinophils, mast cells, macrophages, and activated 
lymphocytes
Regarding the other cell types, no major implications on prognosis 
were observed. In patients with many eosinophils, we noted a trend 
(P = .06) for better OS overall, and, in young patients (<60 years) a 
statistically significantly better OS. Eosinophil cationic protein se-
creted by the eosinophils is cytotoxic to the HRS cells.33 In studies 
where older treatments were used, a high number of eosinophils was 
associated with an adverse prognosis in 2 studies,16,34 but not in 2 
other studies.35,36 The lack of prognostic implication of high mast cell 
infiltration in our data, in contrast to all5,37-39 but 135 previous study, 
could be due to the use of different treatments during the past dec-
ades. Higher proportions of macrophages were noted in patients 
with higher proportion of activated lymphocytes, EBV- positive 
 tumors as well as in patients with bulky tumor. Macrophages can be 
divided into M1 or M2 signature in which the first is connected to 
antitumor immune activity and the other with tumor progression.9 
Hence, macrophages could be further subclassed to give insight into 
their role in the microenvironment. Several studies have found high 
numbers of macrophages measured both by CD68 and CD163 to be 
associated with an adverse prognosis,18,31,38,40-44 while other studies, 
in line with our results, showed no prognostic impact hereof.19,45,46 
For patients with a high number of activated lymphocytes, we noted 
a trend (P = .051) for shorter OS in univariate analyses compared 
to patients with a low number of activated lymphocytes, similar 
to most,5,20,26,29,38 but not all 25,36,47 previous studies. However, in 
our age- adjusted analyses, the high presence of activated lympho-
cytes had no impact on outcome. We found that a high amount of 
 activated lymphocytes correlated with several factors indicating an 
 adverse prognosis, including older age, male sex, and EBV- positivity 
(Table S2). In summary, none of the inflammatory cell types predi-
cated OS in the whole cohort, likely due to effective therapeutic 
rescue strategies for relapsing patients and the excellent prognosis 
in the cohort. Previous investigations could have been highly influ-
enced by the variation in the number of activated lymphocytes and 
these well- known negative prognostic factors, particularly older age.
4.4 | Methods
Immunohistochemical antibodies are not always entirely specific 
for only 1 cell type. FoxP3 is used in all studies as a marker for 
TABLE  2 Hazard ratios (HR) with 95% confidence intervals for time to progression comparing patients with each exposure to the patients 
without this exposure
Exposure No.a Univariate Age- adjusted Age < 60b Age ≥ 60b Stage IA- IIAb Stage IIB- IVb
Male 409 0.95:0.57- 1.56 0.90:0.55- 1.49 0.92:0.51- 1.66 1.09:0.42- 2.84 0.78:0.30- 2.05 0.97:0.54- 1.74
EBV positive 394 1.03:0.58- 1.83 0.94:0.53- 1.69 0.73:0.34- 1.57 1.58:0.61- 4.10 1.08:0.38- 3.06 1.02:0.51- 2.06
Eosinophils >200 398 0.83:0.43- 1.60 0.86:0.45- 1.66 0.84:0.39- 1.81 0.83:0.24- 2.89 0.93:0.26- 3.25 0.76:0.35- 1.63
Mast cells q 4 382 1.45:0.85- 2.47 1.37:0.81- 2.34 1.50:0.80- 2.82 1.50:0.55- 4.07 1.03:0.33- 3.18 1.46:0.79- 2.79
Macrophages q 4 368 0.85:0.49- 1.47 0.85:0.49- 1.47 0.82:0.43- 1.56 0.98:0.36- 2.70 0.96:0.32- 2.85 0.70:0.37- 1.32
Tregs q 4 374 1.71:0.99- 2.95 1.82:1.05-3.15 1.93:1.00-3.73 1.98:0.70- 5.65 0.99:0.31- 3.13 2.24:1.19-4.23
Activated lymphocytes 
q 4
336 1.04:0.53- 2.03 0.93:0.48- 1.84 1.04:0.45- 2.40 0.66:0.21- 2.04 0.98:0.28- 3.51 1.03:0.46- 2.28
Age 409 1.02:1.01-1.04 - 1.02:0.99- 1.04 0.99:0.88- 1.10 1.02:0.99- 1.05 1.02:1.01-1.04
Stage I- IIA vs IIB- IV 407 0.41:0.23-0.71 0.39:0.23-0.69 0.39:0.20-0.76 0.39:0.14- 1.10 - - 
Bulky vs non- Bulky 
tumor
379 1.62:0.93- 2.80 1.76:1.01-3.08 1.49:0.78- 2.84 1.95:0.67- 5.71 1.47:0.49- 4.41 1.51:0.79- 2.86
Bone marrow 
involvement
361 1.95:0.71- 5.41 1.78:0.64- 4.96 1.60:0.39- 6.65 2.33:0.52- 
10.44
Xc 1.52:0.54- 4.27
Albumin, <40 g/L 335 2.15:1.17-3.97 2.04:1.10-3.77 1.80:0.90- 3.58 3.53:0.80- 
15.67
3.83:1.31-
11.21
0.97:0.46- 2.07
q, quartile; EBV, Epstein- Barr Virus; Tregs, Regulatory T lymphocytes.
aNumber of cases with complete information enabling evaluation for time to progression (TTP). Significant results are indicated in bold.
bUnivariate.
cToo few events to present.
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Tregs. However, FoxP3 is also expressed by other lymphocytes 
with no regulatory functions, such as CD4+ T lymphocytes and NK 
cells.48 CD68 is an unspecific marker for macrophages, and results 
have been difficult to reproduce44; however, CD68 has been used 
in all earlier studies in cHL.18,19,31,38,40-46 CD163 is considered to 
be a more specific marker for tumor- promoting macrophages (M2 
macrophages).9,44 To identify activated lymphocytes such as CTLs, 
we used granzyme B, as in most previous studies.20,25,26,36,41,47 
Granzyme B is expressed by activated CTLs after antigen recog-
nition, by NK cells49 but also to some extent by active Tregs.50 
However, the proportion of Tregs did not correlate with the 
proportion of activated lymphocytes (Table S1). This indicates 
a low misclassification risk between active Tregs and activated 
lymphocytes.
4.5 | Strengths and weaknesses
Strengths of our study include the predefined hypothesis, the 
population- based setting with histopathologic review of more than 
90% of the cases, the homogenously treated large cohort, and the 
wide array of inflammatory cell markers evaluated with immunohis-
tochemistry. We also had satisfactory intra- and interindividual repro-
ducibility with our manual evaluation (supplemental text). Limitations 
include the lack of complete information on treatment received for 
the Danish patients; however, HRs for the association between a 
high amount of Tregs and TTP among Swedish patients were similar 
for those treated with ABVD or BEACOPP. Despite being the largest 
cohort to date, limitations of our results include low precision of ef-
fect estimates due to few outcomes. In addition, multiple testing could 
have generated some statistically significant estimates by chance, but 
all cut- offs were decided a priori.
5  | CONCLUSIONS
In summary, cHL can be divided into active, anergic, innate, or mixed 
immune signatures upon diagnosis. We believe that heterogeneous 
populations, gathered over several decades and using different out-
comes in earlier studies could explain most of the differences in prog-
nostic implications of tumor- infiltrating leukocytes between these 
studies and our study. In our study, a high amount of Tregs (anergic) 
indicated a shorter TTP, which we believe could be caused by ineffec-
tive immune- clearance of the malignant HRS cells and resistance to 
contemporary treatment regimens.
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